



05-20-02

RECEIVED 1652

MAY 23 2002

EXPRESS MAIL CERTIFICATE

Date 5/17/02 Label No. 028648435-US

I hereby certify that, on the date indicated above, this paper or fee was deposited with the U.S. Postal Service & that it was addressed for delivery to the Assistant Commissioner for Patents, Washington, DC 20231 by "Express Mail Post Office to Addressee" service.

PLEASE CHARGE ANY DEFICIENCY UP TO \$300.00 OR CREDIT ANY EXCESS IN THE FEES DUE WITH THIS DOCUMENT TO OUR DEPOSIT ACCOUNT NO. 04-0100

TECH CENTER 1600/2900 #4/1652  
05-29-02

Name (Print)

Customer No.:

Signature



07278

PATENT TRADEMARK OFFICE

Docket No.: 4305/1G031US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Tilo SCHWIENTEK, et al.

Serial No.: 10/084,406

Group Art Unit: 1652

Confirmation No.: 8337

Filed: February 25, 2002

Examiner: TBA

For: UDP-N-ACETYLGLUCOSAMINE:GALACTOSE- $\beta$ 1,3-N-ACETYLGLACTOSAMINE- $\alpha$ -R(GLCNAC TO GALNAC) $\beta$ 1,-6-N-ACETYLGLUCOSAMINYLTRANSFERASE, C2GNT3

INFORMATION DISCLOSURE STATEMENT

Hon. Commissioner of  
Patents and Trademarks  
Washington, DC 20231

Sir:

In order to comply with 37 CFR 1.97 and 1.98, attached hereto is a copy of Form PTO-1449. Copies of the documents were filed during prosecution of the parent application Serial No. 09/645,192.

In accordance with MPEP Sections 609 and 707.05(b), it is requested that each document cited (including any cited in applicant's specification which is not repeated on the attached Form PTO-1449) be given thorough consideration and that it be cited of record in the prosecution history of the present application by initialing Form PTO-1449 next to the document. Such initialing is requested even if the Examiner does not consider a cited document to be sufficiently pertinent to use in a rejection, or otherwise does not consider it to be prior art for any reason, or even if the Examiner does not believe that the guidelines for citation have been fully complied with. This is requested so that each document becomes listed on the face of the patent issuing on the present application.

This submission is filed within three months of the filing of the application.


The present Information Disclosure Statement is being submitted in compliance with 37 CFR 1.56, but the citation of such document is not to be construed as an admission that such document is necessarily relevant or prior art. No representation is intended that the cited documents represent the results of a complete search, and it is anticipated that the Examiner, in the normal course of examination, will make an independent search and will determine the best prior art consistent with 37 CFR 1.104(a) and 1.106(b) and, in the course of each search, will review for relevance every document cited on the attached form even if not initialed.

It is believed that no fee is due. However, if the Commissioner determines that a fee is due, the Commissioner is hereby authorized to charge the above deposit account for any deficiency.

Early and favorable consideration is earnestly solicited.


Respectfully submitted,

Dated: May 17, 2002

A handwritten signature in cursive script, appearing to read "Anna Löqvist", is written over a horizontal line.

Anna Löqvist, Ph.D.  
Limited Recognition Under  
37 C.F.R. §10.9(b) (see enclosure)  
Representative for Applicant(s)

DARBY & DARBY  
Post Office Box 5257  
New York, NY 10150-5257  
(212) 527-7700

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1G031US2 SERIAL NO.: 10/084,406  
 APPLICANT: Tilo SCHWIENTEK, et al. FILING DATE: February 25, 2002  
 CONFIRMATION NO.: 8337

**U.S. PATENT DOCUMENTS**

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
-----------------------	--------------------	------	------	-------	----------	-------------

**FOREIGN PATENT DOCUMENTS**

*EXAMINER INITIALS	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
-----------------------	--------------------	------	---------	-------	----------	-----------------------

**OTHER REFERENCES****(INCLUDING AUTHOR, TITLE DATE, PERTINENT PAGES, ETC.)**

*EXAMINER INITIALS
-----------------------

1. Almeida et al., Journ. of Biol. Chem., 1997; 272(51):31979-31991
2. Altschul et al., J. Mol. Biol., 1990; 215:403-410
3. Baum et al., J. Exp. Med., 1995; 181:877-887
4. Bennett et al., Journ. of Biol. Chem., 1996; 271(29):17006-17012
5. Bierhuizen et al., Glycobiology, 1995; 5(4):417-425
6. Bierhuizen et al., Proc. Natl. Acad. Sci. USA, 1992; 89:9326-9330
7. Brockhausen et al., Eur. J. Biochem., 1995; 233:607-617
8. Brockhausen et al., Cancer Research, 1991; 51:1257-1263
9. Clausen et al., Glycobiology, 1996; 6(6):635-646
10. Devereux et al., Nucleic Acids Research, 1984; 12(1)
11. Fukuda, Cancer Research, 1996; 56:2237-2244
12. Higgin, G., et al., J. Biol. Chem., 1991; 266(10):6280-6290
13. Kumar et al., Blood, 1996; 88(10):3872-3879
14. Matteucci et al., J. Am. Chem. Soc., 1981; 103:3185-3191
15. Perillo et al., J. Mol. Med., 1998; 76:402-412
16. Perillo et al., Nature, 1995; 378:736-739
17. Piller et al., Journ. of Biol. Chem., 1988; 263(29):15146-15150
18. Saitoh et al., Blood, 1991; 77(7):1491-1499
19. Schwientek et al., Journ. of Biol. Chem., 2000; 275(15):11106-11113
20. Schwientek et al., Journ. of Biol. Chem., 1999; 274(8):4504-4512
21. Southern, E.M., J. of Mol. Biol., 1975; 98(3):503-517
22. Springer, Science, 1984; 224:1198-1206

TECH CENTER 1600/2900

MAY 23 2002

RECEIVED

**LIST OF REFERENCES CITED BY APPLICANT**

(Use Several Sheets if Necessary)

DOCKET NO.: 4305/1G031US2      SERIAL NO.: 10/084,406  
APPLICANT: Tilo SCHWIENTEK, et al.      FILING DATE: February 25, 2002  
CONFIRMATION NO.: 8337

23. Wandall et al., Journ. of Biol. Chem., 1997; 272(38):23503-23514
24. Williams et al., Journ. of Biol. Chem., 1980; 255(23):11247-11252
25. Yang et al., Glycobiology, 1994; 4(6):873-884
26. Yeh et al., Journ. of Biol. Chem., 1999; 274(5):3215-3221
27. Yoo et al., Journ. of Biol. Chem., 1989; 264(29):17078-17083
28. Yousefi et al., Journ. of Biol. Chem., 1991; 266(3):1772-1782

EXAMINER: \_\_\_\_\_ DATE CONSIDERED: \_\_\_\_\_

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw a line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.